The German life science and medtech private equity firm SHS Capital has made a EUR 10 million investment in Simulands, a Swiss manufacturer of simulation devices for medical training of cardiovascular interventions. The investment aims to
The German life science and medtech private equity firm SHS Capital has made a EUR 10 million investment in Simulands, a Swiss manufacturer of simulation devices for medical training of cardiovascular interventions. The investment aims to